Current Long-Term Pharmacotherapies for the Management of Obesity

Current Long-Term Pharmacotherapies for the Management of Obesity
  • 김보연
  • 강선미
  • 강지현
  • 김경곤
  • 김범택
  • 외 14명
Citations

WEB OF SCIENCE

23
Citations

SCOPUS

29

초록

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.

키워드

ObesityOrlistatLorcaserinLiraglutideNaltrexone/bupropion extended-releasePhentermine/topiramate extended-release
제목
Current Long-Term Pharmacotherapies for the Management of Obesity
제목 (타언어)
Current Long-Term Pharmacotherapies for the Management of Obesity
저자
김보연강선미강지현김경곤김범택김승준김양현김정환김재현남가은박지연손장원신혜정오태정이혁전언주정소정홍용희김종화
DOI
10.7570/jomes20010
발행일
2020-06
저널명
Journal of Obesity & Metabolic Syndrome
29
2
페이지
99 ~ 109